Need a Health professional?

Shreyaansh Lifesciences, Jaipur. India

Sacituzumab Govitecan-hziy Injection 180 mg
Sacituzumab Govitecan-hziy Injection is used to treat a certain type of breast cancer in adults that has spread to other parts of the body or cannot be removed by surgery and who have already been treated with at least two other chemotherapy medications.

Sacituzumab Govitecan-hziy was approved for medical use in the United States in 2020. It is on the World Health Organization’s List of Essential Medicines. It is available as a generic medication.

Sacituzumab Govitecan-hziy Injection Available Price In India UK Saudi Arabia

Sacituzumab Govitecan-hziy Injection

  • Generic Brand Available – Trodelvy
  • API – Sacituzumab Govitecan-hziy
  • Packaging – Glass Bottle
  • Strength – 180 mg

What is Sacituzumab Govitecan-hziy used for?


  • Sacituzumab govitecan-hziy injection is used to treat triple-negative breast cancer that has spread (metastatic) or cannot be removed by surgery (unresectable locally advanced). It is given to patients who have received 2 or more cancer treatments, including at least 1 treatment for metastatic disease.

All Trademarks and Brands that appear on website belong to their respective owners and Ikris Pharma Network does not lay and claim on them we only provide Information. We are NOT ONLINE store and We do not sell Narcotics and Sedatives. Iron Sucrose is a pharmaceutical drug that legally requires a medical prescription to be dispensed. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.

Get Access To Sacituzumab Govitecan-hziy Injection 180 mg

Shreyaansh Lifesciences, Jaipur. India

Shreyaansh Lifesciences is registered in Jaipur, India. Registration Number : 08AEEFS9350K1ZI under GST Act. 
Branch Offices in India : Jaipur | New Delhi

SF-72-73 2ND FLOOR, Jaipur Electronic Market, Ridhi Sidhi Choraha, Jaipur, Rajasthan, 302018.

+91 99292 77766

Facts of Medicines

Sacituzumab Govitecan-hziy Injection 180 mg


Care Sacituzumab Govitecan-hziy Injection must be refrigerated at 2°C to 8°C (36°F to 46°F). Do not use the Sacituzumab Govitecan-hziy Injection beyond the expiration date located on the carton and the vial..


  • Do NOT substitute TRODELVY for or use with other drugs containing irinotecan or its active metabolite SN-38. For intravenous infusion only. Do not administer as an intravenous push or bolus.
  • The recommended dose is 10 mg/kg once weekly on Days 1 and 8 of continuous 21-day treatment cycles until disease progression or unacceptable toxicity.
  • Premedication for prevention of infusion reactions and prevention of chemotherapy-induced nausea and vomiting is recommended.
  • Monitor patients during the infusion and for at least 30 minutes after completion of infusion. Treatment interruption and/or dose reduction may be needed to manage adverse reactions.


  • The following clinically significant adverse reactions can occur with Sacituzumab Govitecan-hziy Injection: Cardiovascular Toxicity, Myelosuppression, Hypersensitivity, Hypertension, Pancreatic Toxicity.


  • Genetic testing should be indicated in order to detect whether a person is at higher risk of developing hypersensitivity.
  • Sacituzumab Govitecan-hziy Injection may not be added as a single agent when antiretroviral regimens are changed because of loss of the virologic response.
  • Patients with liver disease should be watchful and cautious in order to Sacituzumab Govitecan-hziy Injection because it can aggravate the condition.
    In patients with Sacituzumab Govitecan-hziy Injection, conditions like immune reconstitution inflammatory syndrome, a change in body fat as well as an increased risk of heart attack may occur.
  • Sacituzumab Govitecan-hziy Injection is not recommended for use in infants who are under 3 months of age.
  • Cases like lactic acidosis and severe hepatomegaly with steatosis occurred with the use of nucleoside analogues.
  • Sometimes serious hypersensitivity reactions have been associated with Sacituzumab Govitecan-hziy Injection..

    FAQs – Medicine Questions

    Sacituzumab Govitecan-hziy Injection 180 mg
    Is sacituzumab govitecan-HZIY chemotherapy?

    Sacituzumab govitecan-hziy injection is used to treat triple-negative breast cancer that has spread (metastatic) or cannot be removed by surgery (unresectable locally advanced). It is given to patients who have received 2 or more cancer treatments, including at least 1 treatment for metastatic disease.

    What kind of drug is sacituzumab?

    Image result for Sacituzumab Govitecan-hziy uses
    Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer. Sacituzumab govitecan is an antibody–drug conjugate made up of an anti–Trop-2 antibody linked to the chemotherapy drug SN-38.

    How is sacituzumab govitecan given?
    Sacituzumab govitecan-hziy is given as an IV infusion once weekly on Days 1 and 8 of a 21-day treatment cycle.
    Where can I buy Sacituzumab Govitecan-hziy Injection?

    You can buy Sacituzumab Govitecan-hziy Injection from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.

    The buyer should check the existing law in their home country before importing the product.

    What is the procedure to buy Sacituzumab Govitecan-hziy Injection?

    Patients can simply fill the order form or can send mail at Patients can also send WhatsApp messages to +91 99292 77766 / 98738 10020   We will reply ASAP with the details of the Sacituzumab Govitecan-hziy Injection price as well as procurement procedure.

    Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.

    Is Trodelvy an immunotherapy?
    Trodelvy is an immune targeted therapy medicine. It is made up of: sacituzumab, a type of protein called a monoclonal antibody, that targets the Trop-2 protein; the Trop-2 protein is found in more than 90% of triple-negative breast cancers